Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q4 FY21 results · Jan–Mar 2021
Panacea Biotec reported revenue from operations of ₹168.27 crore (up 34.2% from Q4 FY20) and net loss of ₹54.14 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 168.27 | 125.36 | +34.2% | 141.76 | +18.7% |
| Other income | 4.90 | 17.98 | −72.7% | 1.89 | +159.3% |
| Total income | 173.17 | 143.34 | +20.8% | 143.65 | +20.5% |
| Profit before tax | (52.65) | (59.40) | Loss narrowed | (39.96) | Loss widened |
| Net profit for the period | (54.14) | (69.70) | Loss narrowed | (40.05) | Loss widened |
| EPS, basic (₹) | (8.84) | (11.38) | Loss narrowed | (6.54) | Loss widened |
| Net margin (%) | -32.2 | -55.6 | -28.3 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 79.86 | 56.77 | +40.7% | 69.02 | +15.7% |
| Other income | 7.75 | 27.80 | −72.1% | 7.17 | +8.1% |
| Total income | 87.61 | 84.57 | +3.6% | 76.19 | +15.0% |
| Profit before tax | (16.79) | (6.62) | Loss widened | 1.91 | Turned loss |
| Net profit for the period | (18.31) | (32.48) | Loss narrowed | 1.90 | Turned loss |
| EPS, basic (₹) | (2.99) | (5.31) | Loss narrowed | 0.31 | Turned loss |
| Net margin (%) | -22.9 | -57.2 | 2.8 |
Consolidated
- Filed with BSE
- 03 Jun 2021, 19:10 IST
- Board meeting
- 02 Jun 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Jun 2021, 19:10 IST
- Board meeting
- 02 Jun 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE